TCPOBOP |
| Catalog No.GC10567 |
TCPOBOP est un agoniste constitutif du récepteur de l'androstane (CAR) qui induit une prolifération et une hépatomégalie robustes des hépatocytes sans aucune lésion hépatique ni perte de tissu. TCPOBOP atténue les lésions hépatiques murines induites par Fas en modifiant les protéines Bcl-2.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 76150-91-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
TCPOBOP is a constitutive androstane receptor (CAR) agonist that induces robust hepatocyte proliferation and hepatomegaly without any liver injury or tissue loss[1]. TCPOBOP attenuates Fas-induced murine liver injury by altering Bcl-2 proteins[2].
TCPOBOP (oral; 3 mg/kg; 1-5 days) remarkable increases Liver weight to body weight in LW/BW ratio at 48 hours[1].
References:
[1]. Bhushan B, et al. TCPOBOP-Induced Hepatomegaly and Hepatocyte Proliferation are Attenuated by Combined Disruption of MET and EGFR Signaling. Hepatology. 2019 Apr;69(4):1702-1718.
[2]. Baskin-Bey ES, et al. Constitutive androstane receptor (CAR) ligand, TCPOBOP, attenuates Fas-induced murine liver injury by altering Bcl-2 proteins. Hepatology. 2006 Jul;44(1):252-62.
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *